Managing Partner David Stone Comments in a November 5, 2013 BioWorld Today Article, on Pharmaceutical Company Johnson & Johnson’s Agreement to Pay Over $2.2 Billion to Resolve Criminal and Civil Claim

November 12th, 2014

Managing Partner David Stone was quoted in a BioWorld Today article on Johnson & Johnson’s agreement to pay over $2.2 billion to resolve criminal and civil claims of fraud for the improper sale and marketing of drugs, including Risperdal, to vulnerable populations of children and older adults. Stone & Magnanini represented whistleblowers for False Claim Act violations against J&J and its subsidiary, Janssen Pharmaceuticals, Inc.

Marie Power, J&J Will Pay Feds, States $2.2B to Settle Criminal, Civil Actions, BIOWORLD TODAY, Nov. 5, 2013.